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ABSTRACT 
Oral Contraceptive Androgenicity and Cognitive Performance Among Women 
Katherine Alvarez, B.S. 
Mary Spiers, Ph.D. 
 
Oral contraceptives (OCs) may lower endogenous sex hormones while introducing 
synthetic progestins with varying degrees of biological androgenicity or masculinizing 
effects. No study has examined the relationship between OC androgenicity and female 
performance on visuospatial (i.e., line orientation, matrix reasoning), verbal (i.e., word 
memory, analogical reasoning) and facial expression processing (i.e., emotion 
recognition, emotion intensity differentiation). We hypothesized a positive relationship 
between androgen status and line orientation, matrix reasoning and analogical reasoning 
performance and a negative relationship between androgen status and word memory, 
emotion recognition and emotion intensity differentiation. One hundred seventy nine 
females  (82.1% Caucasian) ages 15-21 from the Philadelphia Neurodevelopmental 
Cohort were assigned to groups based on the androgenicity of their OC progestins: 
"highly androgenic” (Levonorgestrel), “androgenic” (Norethindrone), “antiandrogenic” 
(Drospirenone) and controls. A multivariate analysis of variance revealed that composite 
emotion recognition performance was significantly different among groups F(6,348) = 
2.23, p < .05; Wilk's Λ = 0.927, partial η2 =.037. Univariate one-way analyses of 
variance revealed marginally significant emotion recognition  (p = .107, partial η2 
=.034) and emotion intensity differentiation (p = .064, partial η2 =.040) among groups.  
Tukey’s post hoc tests revealed that “highly androgenic” OC users (M = 81.85, SD = 
8.21) outperformed controls (M = 77.05, SD = 8.25) on emotion intensity differentiation.  
There were no differences in line orientation, matrix reasoning, word memory, analogical 
  xi 
reasoning, anger recognition or anger intensity differentiation.  Findings suggest that 
some aspects of facial expression processing (i.e., emotion intensity) may be more 
sensitive to sex hormone changes than others (i.e., emotion recognition).  Emotion 
intensity differentiation patterns suggest that OCs may not exert clinically meaningful 
androgenic effects on cognition.
  1 
 
CHAPTER 1: BACKGROUND AND LITERATURE REVIEW 
 Oral contraceptives (OCs) or “birth control pills” present an avenue to explore 
female cognitive performance because they alter sex hormones that may be implicated in 
cognition (Erlanger, Kutner, & Jacobs, 1999).  The following literature review examines 
female cognitive performance changes in the visuospatial, verbal, and social facial 
expression processing domains with natural and pharmacologically induced hormonal 
fluctuations.  The hormone-altering effects of OCs are discussed in relation to the 
pharmacology and the biological androgenicity parameters of the three progestins of 
interest to the current study – Levonorgestrel, Norethindrone and Drospirenone.  Lastly, 
existing literature on the androgenizing “masculinizing” and antiandrogenizing “anti-
masculinizing” cognitive effects of different OC progestins is summarized across 
visuospatial, verbal, and facial expression processing domains.  
 
1.1 Activating Effects of Sex Hormones on Cognition 
Sex hormones (estrogen, progesterone, testosterone) may differentially “organize” 
the prenatal brains of males and females, with higher testosterone levels in males 
resulting in “masculinized” cognitive patterns and the absence or near absence of 
testosterone in females resulting in “feminized” cognitive patterns.  Sex hormone 
fluctuations throughout the life span may “activate” or facilitate processing in previously 
organized brain structures and neural networks leading to cognitive performance 
differences between males and females (Kelso, Nicholls, & Warne, 1999; Kimura, 1996).  
The organizing effects of sex hormones are believed to be permanent whereas the 
activating effects are thought of as temporary and reversible.  Throughout the present 
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study “female-typical” (FT) and “male-typical” (MT) will used in reference to cognitive 
performance patterns that are typical of that sex in comparison to the opposite sex. 
 
1.1.1 Activating Effects of the Menstrual Cycle  
 The “activating” role of sex hormones is supported by studies of cognitive 
performance variations in females across the menstrual cycle.  The menstrual cycle is 
divided into three phases (menstrual, follicular, and luteal) that correspond with patterns 
of hormonal fluctuations.  Estrogen and progesterone are lower during the menstrual 
phase, gradually increase in the follicular phase and peak at mid-cycle during the luteal 
phase (Hampson & Young, 2007).  Although the literature mainly reports cycle-related 
variations in estrogen and progesterone, testosterone levels also fluctuate throughout the 
menstrual cycle.  Studies suggest that in women, testosterone levels are at their lowest 
during the late luteal, menstrual and early follicular phases, progressively increase 
throughout the follicular phase and peak between the late follicular and early luteal 
phases of the menstrual cycle (Guay, 2002; Massafra, De Felice, Agnusdei, Gioia, & 
Bagnoli, 1999; Rothman et al., 2011; Salonia et al., 2008). 
 Although not all findings are consistent, the higher estrogen and progesterone 
(luteal) phase of the menstrual cycle has been associated with more accurate (FT) verbal 
fluency performance (Maki, Rich, & Rosenbaum, 2002; Rosenberg & Park, 2002; Solís-
Ortiz & Corsi-Cabrera, 2008).  Conversely, studies show that during menstruation and 
the early follicular phase, when estrogen and progesterone are at their lowest, there is a 
slight shift in women’s cognitive performance towards the MT pattern of increased 
accuracy in visuospatial performance (Hampson, 1990; Hausmann, Slabbekoorn, Van 
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Goozen, Cohen-Kettenis, & Gunturkun, 2000; Maki et al., 2002; Silverman & Phillips, 
1993) (See Figure 1). 
 Most studies exploring sex hormone fluctuations and female social cognition 
performance via facial expression processing (FEP) report a negative association between 
FEP performance and estrogen and progesterone levels.  Contrary to the cycle-related 
performance patterns observed with visuospatial and verbal fluency measures, more 
accurate (FT) FEP performance is observed during the early follicular cycle phase when 
estrogen and progesterone levels are lower and less accurate (MT) FEP performance is 
observed during the luteal phase when estrogen and progesterone are higher (See Figure 
1).  Although these studies do not report cycle-related testosterone variations, it is 
important to note that in women, testosterone levels are also lower during the early 
follicular phase and peak between the late follicular and early luteal phases (Guay, 2002; 
Massafra et al., 1999; Rothman et al., 2011; Salonia et al., 2008).  A series of studies by 
Derntl and colleagues (2008a, 2008b, 2013) consistently report more accurate FEP 
performance in the early follicular phase than in the luteal phase.  Similarly, a 2009 study 
by Guapo and colleagues reported more accurate recognition of angry faces and a nearly 
significant trend of more accurate recognition of fearful faces in the early follicular 
phase.  Only one study to date has reported incongruous results of more accurate fear 
recognition during the luteal than the follicular phase (Pearson & Lewis, 2005).  Unlike 
the aforementioned studies, Pearson and Lewis (2005) did not confirm estrogen and 
progesterone levels via hormonal assays and did not estimate cycle phase on testing day.  
Cycle phase was estimated at a later date based on participant-initiated email reports of 
the onset of menses following study participation, potentially introduced additional error 
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to the study’s cycle estimates and confounding results.  For example, reporting a menses 
date that is off by a couple of days is enough to erroneously place a late follicular/early 
luteal (higher estrogen and progesterone) participant in the “low hormone” follicular 
group or to place a late luteal - approaching menses (lower estrogen and progesterone) 
participant in the “high hormone” luteal group. 
 
 1.1.2 Activating Effects of Testosterone 
 The “activating” role of sex hormones on female cognition has also been 
supported by studies demonstrating a shift towards male-typical performance patterns 
with higher endogenous (naturally occurring) testosterone levels and exposure to 
exogenous (synthetic) testosterone.  The literature suggests more accurate performance 
on visuospatial tasks in women with higher salivary testosterone concentrations (Gouchie 
& Kimura, 1991; Moffat & Hampson, 1996; Ostatnikova, Putz, Celec, & Hodosy, 2009) 
as well as in women who are exposed to synthetic testosterone (Aleman, Bronk, Kessels, 
Koppeschaar, & Van Honk, 2004; Hirshman et al., 2004).  Additionally, in a series of 
testosterone administration studies in women, Van Honk and colleagues (2007, 2011) 
reported decreased sensitivity to fear facial expressions, a significant reduction in 
sensitivity to facial anger, and significant impairment in the ability to infer emotions, 
intentions, and other mental states from the eyes region of the face after a single dose of 
testosterone. 
 Lastly, compelling evidence of the “activating” role of sex hormones on cognition 
has been gathered from studies of female-to-male transsexuals undergoing testosterone 
treatments.  In their 1994 study, Van Goozen and colleagues reported male-typical 
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cognitive patterns of increased accuracy in visuospatial performance (measured via the 
Mental Rotation Task (MRT)) and declines in female-typical verbal fluency performance 
after three months of testosterone treatments.  In a follow-up study, Slabbekoorn et al. 
(1999) replicated Van Goozen’s findings of stronger visuospatial performance in female-
to-male transsexuals and demonstrated that these effects did not quickly reverse; lasting 
up to five weeks after terminating testosterone treatments.  No deteriorating effects on 
verbal fluency were identified (Slabbekoorn, Van Goozen, Megens, Gooren, & Cohen-
Kettenis, 1999).  There are studies however, that report no relationship between 
testosterone levels and spatial or verbal performance in women (Halari et al., 2006; Puts 
et al., 2010). 
 
 1.1.3 Sex Hormones and Brain Activation 
 Currently, one of the most comprehensive theoretical models to integrate sex 
hormones, brain activation and sex differences in visuospatial and verbal cognitive 
performance may be Hampson’s (1990) differential activation theory.  Hampson (1990) 
theorized that sex hormone differences in males and females may differentially activate 
the cerebral hemispheres, leading to sex differences in cognitive performance.  Hampson 
suggested that higher estrogen and progesterone levels (e.g., luteal phase) may cause 
increased activation of the left hemisphere (where language is typically mediated) while 
simultaneously inhibiting right hemisphere functioning (where visuospatial processing is 
typically mediated).  This differential activation pattern is believed to result in females 
outperforming males in verbal cognitive tasks as well as females with higher estrogen 
and progesterone levels (greater left hemisphere activation) outperforming females with 
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lower estrogen and progesterone levels (decreased left hemisphere activation) in verbal 
cognitive tasks.  Conversely, lower estrogen and progesterone levels (i.e., menstrual 
phase) were theorized to result in decreased left hemisphere activation and enhanced right 
hemisphere activation, leading to increased visuospatial performance accuracy in males 
over females as well as in females with lower estrogen and progesterone levels over 
females with higher estrogen and progesterone levels (Hampson, 1990).  
 Although females consistently outperform males on FEP measures and do so as 
early as infancy, the underlying mechanisms are not well understood (Hall, Hutton, & 
Morgan, 2010; McClure, 2000).  Currently, there is no leading model to account for sex 
differences in FEP performance however some researchers theorize that sex hormones 
may play a moderating role (Mareckova et al., 2012).  For example, sex differences in 
exploratory eye movements tend to emerge alongside the hormonal changes of puberty 
(Miyahira, Morita, Yamaguchi, Nonaka, & Maeda, 2000) and eye-tracking methods have 
revealed that females tend to show increased fixations and dwell time to the eyes, which 
may account for their stronger performance on facial expression recognition (Hall et al., 
2010).  Interestingly, a single dose of synthetic testosterone has been shown to 
significantly impair women’s ability to infer emotions specifically from the eyes region 
of the face (Van Honk et al., 2011).  Additionally, poor FEP performance has been 
observed after testosterone administration (Van Honk & Schutter, 2007) and during the 
luteal cycle phase when natural testosterone levels are higher (Dernt et al., 2008a, 2008b, 
2013; Guapo et al., 2009). 
 In conclusion, the literature suggests that sex hormones (estrogen, progesterone, 
testosterone) fluctuations are related to changes in female cognitive performance.  
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Menstrual cycle related increases in estrogen and progesterone at mid-cycle are 
associated with increased verbal fluency (female-typical) performance whereas decreased 
estrogen and progesterone during the menstrual and early follicular phases are associated 
with increased visuospatial (male-typical) performance.  A reversed pattern of decreased 
FEP accuracy (male-typical) is observed at mid-cycle when estrogen and progesterone as 
well as testosterone are higher.  The relationship between sex hormones and female 
cognition is supported by studies showing a shift towards male-typical cognitive 
performance in the verbal fluency, visuospatial and FEP domains with synthetic 
testosterone administration.  Although the underlying mechanism is unknown, these 
collective findings suggest a relationship between natural and exogenous (synthetic) sex 
hormones and female cognitive performance.  Oral contraceptives (OCs) are a popular 
group of hormone-altering medications used primarily for pregnancy prevention.  As 
discussed below, OCs alter endogenous sex hormones and contain exogenous (synthetic) 
hormones, warranting research of their usage and female cognitive performance. 
 
 1.2 Hormonal Effects of Oral Contraceptives 
 Although OCs exist in progestin-only pills (“mini-pills”) for patients in whom 
estrogen is not tolerated or contraindicated (Zurawin & Ayensu-Coker, 2007), most 
modern OCs available in the U.S. contain a combination of ethinyl estradiol (synthetic 
estrogen) and 1 of 10 progestin types (synthetic progesterones) (Amy & Tripathi, 2009).  
 The progestins in OCs are mainly responsible for their contraceptive effect while 
the accompanying ethinyl estradiol improve cycle control and augment the progestin’s 
contraceptive efficacy (Zurawin & Ayensu-Coker, 2007).  The estradiol/progestin 
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combination in OCs disrupts a female’s natural menstrual cycle, preventing ovulation and 
the hormonal fluctuations of each cycle phase.  As a result, circulating levels of estrogen 
and progesterone are reduced by at least 50% than those found in regularly menstruating 
women (Gordon & Lee, 1993).  The majority of studies comparing the hormonal profiles 
of OC users and non-users report lower estrogen, progesterone and testosterone levels in 
OC users (Kuhl, Gahn, Romberg, Marz & Taubert, 1985; Mordecai, Rubin, & Maki 
2008; Schultheis, Dargel, & Rhode, 2003; Thorneycroft et al., 1999; Timmons, Hamadeh, 
Devries, & Tarnopolsky, 2005) that closely resemble menstrual-like levels (Schultheiss et 
al., 2003; Thorneycroft et al., 1999).  Additionally, OCs contain different progestins with 
varying degrees of androgenic (masculinizing) or antiandrogenic (anti-masculinizing) 
biological effects that may further alter female sex hormone levels (Batur, Elder, & 
Mayer, 2003). 
 
 1.2.1 Oral Contraceptive Progestins: Generations and Formulations 
 The progestins used in OCs are divided into so-called generations based on when 
they were developed and their biological androgenicity levels.  First generation (no 
longer prescribed for pregnancy prevention), second generation (e.g., Norethindrone, 
Levonorgestrel), third generation (e.g., Norgestimate, Desogestrel) and fourth or new 
generation (e.g., Drospirenone) (Kiley & Hammond, 2007).  
 Second generation progestins are chemically related to testosterone and are 
considered to be the most biologically androgenic progestins on the market.  Third 
generation progestins were developed later and contain structural modifications to lower 
their androgenicity and are therefore considered less biologically androgenic.  Lastly, 
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fourth or new generation progestins were created to contain antiandrogenic components 
and are therefore considered biologically antiandrogenic (Batur et al., 2003; Rowlands, 
2003).  In conclusion, all but fourth generation (antiandrogenic) progestins are considered 
biologically androgenic to some degree. 
 In addition to differences in androgenicity, OCs also differ in the amount of 
progestins delivered across each pack.  Most OCs are either triphasic - delivering 
increasing amounts of progestins from week to week or monophasic formulations that 
deliver a constant dose of ethinyl estradiol and progestin across the pack (Batur et al., 
2003; Kiley & Hammond, 2007).  Historically, monophasic OCs contained 21 active pills 
and 7 inactive pills to mimic the prototypical 28-day menstrual cycle however, 
monophasic formulations are also available in 24 active/ 4 inactive pill packs (Zurawin & 
Ayensu-Coker, 2007) as well as 91-day extended cycle packs (e.g., Seasonale, 
Seasonique) containing 84 active pills and 7 inactive pills.  
 For the purposes of this study, only monophasic OCs containing the “androgenic” 
second generation progestins Levonorgestrel  and Norethindrone and the 
“antiandrogenic” fourth generation progestin Drospirenone will be considered as these 
progestins represent the two extremes of the OC androgenicity spectrum and have not 
been thoroughly studied within the context of female cognitive performance. 
 In summary, OCs alter female sex hormones by a) preventing ovulation and the 
natural hormonal fluctuations of the menstrual cycle, b) lowering sex hormones to 
menstrual-like levels, and c) exposing users to progestins with varying degrees of 
biological androgenicity.  Given that all OCs prevent hormonal fluctuations and lower 
sex hormones, warrants study of their androgenicity differences, especially as they relate 
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to changes in female cognitive performance.  Androgenic and antiandrogenic OC 
formulations are especially relevant to exploring sex hormone related cognitive changes 
as they represent the two extremes of the OC androgenicity spectrum. 
 
1.3 Oral Contraceptive Progestins: Biological Androgenicity/Antiandrogenicity 
 At the cosmetic level, signs of a progestin’s biological androgenicity or 
masculinizing effects may include acne, hirsutism (abnormal hair growth), and weight 
gain.  At a pharmacological level, the literature primarily cites the following as markers 
of a progestin’s biological androgenicity: a) binding to androgen receptors, and b) 
binding to sex hormone binding globulin (SHBG) and subsequent changes on free 
testosterone levels (Greer, Modugno, Allen & Ness, 2005).  Some researchers however, 
argue that no currently available OC has clinically meaningful androgenic effects 
(Stanczyk, 2003; Thorneycroft et al., 1999).  In the following paragraphs the biological 
androgenicity parameters and the counterarguments to each parameter will be discussed 
for the three progestins of interest to the present study: Levonorgestrel, Norethindrone 
and Drospirenone. 
 
 1.3.1 Progestin Androgenicity and Relative Binding Affinity 
 A progestin’s biological androgenicity is mainly determined by measuring its 
androgenic relative binding affinity (RBA) or capacity to bind to androgen receptors in 
the body and central nervous system compared with that of testosterone (Carr, 1998; 
Kumar, Koide, Tsong & Sundaram, 2000).  Levonorgestrel is chemically related to 
testosterone and is generally considered in the literature as one of the most androgenic 
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OC progestins (Sitruk-Ware, 2008).  The binding capacity of Levonorgestrel to androgen 
receptors has been gathered from animal studies (Kumar et al., 2000; Phillips, Hahn & 
Klimek, 1987; Phillips, Demarest, Hahn, Wong & McGuire, 1990) and is reported to be 
approximately 70% that of testosterone (Kumar et al., 2000).  Norethindrone is also 
chemically related to testosterone and considered an androgenic progestin (Stanczyk, 
2003) albeit, less androgenic than Levonorgestrel.  By compiling data from various 
studies of progestin androgenicity, Greer and colleagues (2005) concluded that 
Levonorgestrel is approximately 1.25 times more androgenic than Norethindrone (Greer, 
Modugno, Allen & Ness, 2005).  
 Drospirenone on the other hand, was designed to be biologically antiandrogenic 
by competitively inhibiting binding to androgen receptors in the body and central nervous 
system (Batur et al., 2003; Krattenmacher, 2000; Rowlands, 2003).  Animal studies of the 
binding capacity of antiandrogenic Drospirenone to androgen receptors report binding 
affinities as low as 0.6% to 2% that of testosterone (Krattenmacher, 2000; Muhn, 
Krattenmacher, Beier, Elger, & Schillinger, 1995). 
 Some researchers however, criticize the use of androgen receptor binding data 
from animal studies as evidence of a progestin’s biological androgenicity, citing that 
these findings may not be relevant to humans given major differences between rats’ 
tissues and female tissues and given that these studies employed considerably higher 
progestin doses than those found in OCs (Stanczyk, 2003; Thorneycroft et al., 1999).  For 
example, the Levonorgestrel dosage needed to cause prostate growth in the male rat is 
approximately a thousand times higher than the dosage needed to inhibit ovulation in the 
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female rat; demonstrating that even in rats, the contraceptive dosage of Levonorgestrel 
would have no androgenic effects (Thorneycroft et al., 1999).  
 
 1.3.2 Progestin Androgenicity and Sex Hormone Binding Globulin  
 The second biggest marker of a progestin’s biological androgenicity is derived 
from measuring levels of sex hormone binding globulin (SHBG), the major carrier 
protein for endogenous testosterone.  SHBG binds to free testosterone and this 
determines the amount of free testosterone that remains in the blood (Van der Vange, 
Blankenstein, Kloosterboer, Haspels, & Thijssen, 1990).  Free testosterone is defined as 
the fraction of testosterone that is bioavailable- or able to pass from the blood into bodily 
tissues where it can exert its biological (i.e., androgenic) activity (Baird, Horton, 
Longcope, & Tait, 1969).  Free testosterone levels are therefore considered indicators of 
androgen concentrations in humans (Cumniings & Wall, 1985).  Elevated estrogen levels 
increase SHBG concentrations leading to greater free testosterone binding and thus a 
decrease in free testosterone levels.  Conversely, elevated androgens (i.e., testosterone) 
reduce SHBG levels resulting in increased free testosterone levels in the blood 
(Anderson, 1974; Lobl, 1981).   
 Second generation oral contraceptives containing progestins like Levonorgestrel 
and Norethindrone are considered biologically androgenic because they counteract the 
increase in SHBG brought on by their ethinyl estradiol component and result in more 
bioavailable testosterone (Janaud, Rouffy, Upmalis, & Dain, 1992; Makhzangy, Wynn, & 
Lawrence, 1979; Palatsi et al., 1984; Thorneycroft et al., 1999).  Conversely, 
Drospirenone does not bind to SHBG therefore OCs containing Drospirenone do not 
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reduce the SHBG increase brought on by their estradiol component (Krattenmacher, 
2000).  Drospirenone is therefore considered biologically antiandrogenic, as greater 
SHBG levels equate with more binding of circulating testosterone and therefore less 
bioavailable free testosterone for action at the receptor level (Sitruk-Ware, 2008). 
 Although research findings suggest that older “androgenic” progestins result in 
lower SHBG levels than those observed with newer “antiandrogenic” progestins and 
estradiol alone, researchers warn against using these parameters as evidence of biological 
androgenicity, citing that all OCs (irrespective of progestin type and dose) increase 
SHBG and decrease all endogenous sex hormones including free testosterone levels 
(Stanczyk, 2003; Thorneycroft et al., 1999).  Various research studies report lower free 
testosterone levels in OC users than in naturally cycling females regardless of progestin 
generation (Knopp et al., 2001; Thorneycroft et al., 1999; Van der Vange et al., 1990; 
Van Rooijen, Silveira, Hamsten, & Bremme, 2004; Wiegratz et al., 2003) suggesting that 
OCs may actually exert hypoandrogenic biological effects (Bachmann, 2002; 
Thorneycroft et al., 1999).  Additionally, the hypoandrogenic effects of OCs may account 
for their widespread use for the treatment of hyperandrogenicity-related disorders like 
hirsutism (excessive hair growth) and acne (Stanczyk, 2003; Thorneycroft et al., 1999).  
 Some researchers however, argue that the standard hormonal assays commonly 
used in research were designed to measure endogenous estrogen, progesterone and 
testosterone and are therefore not sensitive enough to accurately detect synthetic OC sex 
hormones (Hampson & Young, 2007).  For example, a 2003 review of ten widely used 
hormonal assays for testosterone found that only two met reasonable validity criteria for 
measuring testosterone in females (Taieb et al., 2003). 
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 In summary, the literature recognizes Levonorgestrel as the most biologically 
androgenic progestin, Norethindrone as androgenic and Drospirenone as an 
antiandrogenic progestin.  Some researchers however, claim that the methods used to 
establish those androgenicity parameters are invalid in humans and that all OCs 
(androgenic and antiandrogenic formulations) lower endogenous testosterone levels and 
are therefore biologically hypoandrogenic.  Lastly, there is concern that standard 
hormonal assays are not sensitive enough to measure synthetic OC sex hormones. 
Overall, these contradictions in the literature suggest that the true hormonal profiles and 
biological androgenicity of OC users is unclear.  This warrants the study of the cognitive 
performance patterns of users of highly androgenic and antiandrogenic OCs, as findings 
of “androgenized” (masculinized) or “antiandrogenized” (antimasculinized) cognitive 
performance will shed light on the true biological androgenicity of different OC types. 
 
1.4 Oral Contraceptives and Female Performance Across Cognitive Domains 
 Although the mechanism of action remains unknown, the literature suggests that 
androgenic OCs have an “androgenizing” or masculinizing effect on female cognitive 
performance for some measures with established sex differences.  In this context, 
“androgenizing” refers solely to the shift towards male-typical and away from female-
typical cognitive performance observed in users androgenic OCs.  Additionally, some 
studies suggest that antiandrogenic OC formulations may have “antiandrogenizing” or 
antimasculinizing cognitive effects; shifting performance on some cognitive measures 
towards female-typical patterns.  Antiandrogenic OCs are newer and less studied than 
androgenic OCs.  It is important to note that few studies in the OC literature have 
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controlled for OC formulation; grouping females with heterogeneous hormonal profiles 
without considering how their hormonal differences may relate to changes in cognitive 
performance.  Additionally, few studies have taken into account progestin generation and 
subsequent variability in the biological androgenicity of different OCs. 
 
 1.4.1Visuospatial Performance and Sex Hormones 
 Although not all findings are consistent, more accurate visuospatial performance 
has been observed in users of androgenic OCs compared to non-users (McFadden, 2000; 
Silverman & Phillips, 1993, Wharton et al., 2008).  Visuopatial performance is generally 
defined as the ability to generate, represent, transform and recall information about an 
object’s shape in space (Linn & Petersen, 1995) and can be broken down into specific 
categories, among them mental rotation (Linn & Petersen, 1995) and spatial orientation 
(Lawton & Morrin, 1999).  Mental rotation refers to the ability to mentally rotate two or 
three dimensional figures (Linn & Petersen, 1995) while spatial orientation is defined as a 
complex set of skills used to locate an object with respect to a point of reference or a 
system of coordinates (Lawton & Morrin, 1999). 
 The Mental Rotation Task (MRT) by Shepard and Metzler (1971) is a commonly 
used spatial measure in OC studies because it has been shown to produce the largest and 
most consistent sex differences in spatial performance favoring males (Linn & Petersen 
1985; Masters & Sanders, 1993; Voyer, Voyer, & Bryden, 1995).  Increased accuracy in 
female MRT performance have been observed with lower endogenous sex hormone 
levels in the menstrual phase (Silverman & Phillips, 1993), higher endogenous 
testosterone levels (Gouchie & Kimura, 1991; Moffat & Hampson, 1996; Ostatnikova et 
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al., 2002) synthetic testosterone administration (Aleman et al., 2004) and testosterone 
treatments (Van Goozen et al., 1994).  The majority of OC studies exploring visuospatial 
performance have focused on the MRT and on users of androgenic OCs (Gordon & Lee, 
1993; McFadden, 2000; Mordecai et al., 2008; Rosenberg & Park, 2002; Silverman & 
Phillips, 1993) and have reported contradictory findings.  Silverman and Phillips (1993) 
and McFadden (2000) reported that OC users outperformed non-users on the MRT 
whereas the remaining studies reported no differences on the MRT performance of OC 
users and nonusers (Gordon & Lee, 1993; Mordecai et al., 2008; Rosenberg & Park, 
2002) 
 To date, only two studies have examined OC progestin androgenicity and spatial 
performance via the MRT.  Wharton and colleagues (2008) reported a trend for women 
using highly androgenic OCs to outperform nonusers but most importantly, women using 
antiandrogenic OCs were found to perform significantly worse than nonusers; suggesting 
that the antiandrogenic components of newer OCs may actually hinder male-typical 
spatial performance.  The second study by Griksiene and Ruksensas (2011) did not 
replicate Wharton’s findings, but a similar trend of hindered MRT performance was 
observed in antiandrogenic OC users. 
 The Judgement of Line Orientation Test (JLO) (Benton, Varney & Hamsher, 
1978) and the Judgement of Line Angle and Position Test (JLAP) (Collaer & Nelson, 
2002) are a set of similar paper and pencil spatial orientation measures that have also 
revealed sex differences favoring males (Collaer & Nelson, 2002; Lindgren & Benton, 
1980; Glamser & Turner, 1995).  Sex differences favoring males have also been observed 
in computerized versions of these measures- JLAP-15 (Collaer, Reimers, & Manning, 
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2007) and CJOLO (Gur et al., 2001; Gur et al., 2010; Gur et al., 2012).  To date, the only 
study to examine JLO performance and OC use did not report significant differences 
between OC users and non-users (Goyette, McCoy, Kennedy, & Sullivan, 2011).  This 
study however, did not control for OC formulation or progestin generation. 
 The Raven’s Progressive Matrices Test (RPM) (Raven, 1960) is a paper and 
pencil measure of nonverbal reasoning that has shown consistent performance differences 
favoring males in two meta-analyses (Irwing & Lynn, 2005; Lynn & Irwing, 2004).  A 
recent computerized version of the RPM has also revealed sex differences favoring males 
in 18-21 year olds (Gur et al., 2012).  Some researchers suggest that these sex differences 
in performance may be related to the fact that many items on the RPM are expressed in 
spatial form (e.g., geometric figures) (Abad, Colom, Rebollo, & Escorial, 2004; Hyde, 
Fennema, & Lamon, 1990), warranting additional research to explore whether there is a 
relationship between performance on the RPM and OC androgenicity or 
antiandrogenicity.  To date, no studies have examined RPM performance and sex 
hormone changes or OC use. 
 
 1.4.2 Verbal Performance and Sex Hormones 
 Verbal fluency measures are commonly used to explore sex differences in verbal 
performance and typically assess participants’ ability to rapidly produce words that start 
with a given letter (e.g. F) over a 60 second period while they monitor word production to 
ensure no words are repeated (Gourovitch, Goldberg, & Weinberger, 1996).  Females 
generally tend to outperform males on tests of verbal fluency (Halari et al., 2006; 
Hampson, 1990; Hausmann, Schoofs, Rosenthal & Jordan, 2009; Weiss, Kemmler, 
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Deisenhammer, Fleischhacker, & Delazer, 2003).  Some studies report increased verbal 
fluency with higher estrogen and progesterone levels (Hampson, 1990; Maki et al., 2002; 
Rosenberg & Park, 2002; Solís-Ortiz & Corsi-Cabrera, 2008) while others report no 
relationship between sex hormone levels and verbal fluency performance (Halari et al., 
2005; Mordecai et al., 2008).  Likewise, some researchers report decreased verbal fluency 
with testosterone treatments (Van Goozen et al., 1994; Van Goozen, Cohen-Kettenis, 
Gooren, Frijda, & Van de Poll, 1995) while others report no relationship between 
testosterone and verbal fluency (Moffat & Hampson, 1996; Slabekoorn et al., 1999).  
Few studies have explored verbal fluency and OC use. Mordecai et al. (2008) reported no 
difference in the verbal fluency performance of OC users and non-users but did not 
control for OC formulation or progestin generation.  To date, the only study of verbal 
fluency to control for OC androgenicity levels reported that naturally cycling females 
outperformed females using androgenic OCs and females using antiandrogenic OCs 
(Griksiene & Ruksensas, 2011).  
 Some research studies report that females tend to outperform males on measures 
of verbal episodic memory.  Verbal episodic memory is commonly assessed by first 
presenting participants with a word and later asking them to recall or recognize the 
earlier-presented word (Herlitz & Rehnman, 2008).  Verbal episodic memory studies  
using paper and pencil tests of word recognition report sex differences favoring females 
when words are presented auditorily (Herlitz, Nilsson, & Bäckman, 1997) and visually 
(Temple & Cornish, 1993; Zelinski, Gilewski, & Schaie, 1993).  Additionally, a series of 
studies exploring verbal episodic memory for visually presented words via a 
computerized word recognition task- the Penn Word Memory Test (CPW) have reported 
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sex differences generally favoring females (Gur et al., 2001; Gur et al., 2010) and 
specifically among 20-21 year olds (Gur et al., 2012).  Verbal episodic memory is not 
well studied within the context of hormonal fluctuations or OC use.  In their 2004 study, 
O’Reilly and colleagues used a visually presented episodic word memory test and 
reported no differences in performance across two phases of the menstrual cycle 
(menstrual and luteal).  Using a similar visually presented word recognition task, 
Wharton and colleagues reported no differences in the verbal episodic memory of 
females across menstrual phases or OC progestins (androgenic vs. antiandrogenic) 
(Wharton et al., 2008).  
 Verbal reasoning via verbal analogies is a less studied verbal subdomain.  Some 
studies report sex differences favoring males on measures of verbal analogies (Lim, 
1994; Gur et al., 2012) while others report no differences in performance (Feingold, 
1988) or in the fMRI activation patterns of males and females during verbal reasoning 
(Gur et al., 2000).  To date, no study has explored analogical reasoning within the context 
of sex hormone changes or OC use. 
 
 1.4.3 Facial Expression Processing and Sex Hormones 
 Facial expression processing (FEP) or the ability to decode facial expression is 
broadly defined to include performance on a variety of tasks including facial expression 
discrimination, recognition and identification (McClure, 2000).  In a 2000 meta-analysis, 
McClure reported a significant female advantage in FEP performance in infancy, 
childhood and adolescence (McClure, 2000).  The female FEP advantage is also seen on 
computerized measures of emotion identification (Gur et al., 2010; Gur et al., 2012; 
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Montagne, Kessels, Frigerio, de Haan, & Perrett, 2005).  Additionally, females tend to be 
more sensitive than males at labeling images of facial expressions that could signal threat 
such as anger and disgust (Montagne et al., 2005).   
 Changes in female FEP performance have been observed with cycle-related 
hormonal fluctuations in studies using computerized emotion identification measures.  
Two studies using Ekman and Friesen’s (1976) Pictures of Facial Affect Series reported 
conflicting results of increased facial emotion recognition accuracy with higher estrogen 
and progesterone levels (Pearson & Lewis, 2005) and increased facial emotion 
recognition accuracy with lower estrogen and progesterone levels (Guapo et al., 2009).  
As previously discussed, Pearson and Lewis’ (2005) findings may have been confounded 
by relying on a delayed self-report to estimate cycle phase during testing day.  A series of 
studies by Derntl and colleagues (2008a, 2008b, 2013) that used a similar emotion 
identification measure - the computerized Vienna Emotion Recognition Task developed 
by Gur and colleagues (2002) also reported improved facial emotion recognition 
accuracy with lower estrogen and progesterone levels. 
 In addition to using images of full-blown facial expressions, FEP studies have 
further explored emotion recognition via images of faces with various degrees of emotion 
intensity.  Using computerized measures of morphed facial expressions, Montagne and 
colleagues (2005) revealed that females were generally more accurate than males at 
labeling facial expressions and more sensitive at recognizing subtle facial expressions, 
particularly for anger and disgust (Montagne et al., 2005).  Sensitivity in that study was 
defined as the average amount of expression intensity needed to correctly identify an 
emotion.  Interestingly, Montagne et al. (2005) noted that whereas females outperformed 
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males at labeling anger and disgust facial expressions with less emotion intensity, they 
were as accurate as males when overall performance (i.e., all intensities together) on each 
expression was analysed.  A series of follow-up studies by Hoffman et al. (2010) using a 
similar paradigm did not replicate the previous finding of a general female advantage for 
faces displaying intense emotions but it did report increased female accuracy for 
recognizing subtle facial displays of emotion, particularly for low (40%-50%) to mid 
(60%-70%) intensity disgust faces (Hoffman, Kessler, Eppel, Rukavina, & Traue, 2010).   
 Lastly, a 2007 study using morphed facial expressions reported decreased FEP accuracy 
in females, particularly for anger faces, after testosterone administration (Van Honk & 
Schutter, 2007).  
 To date, no study has compared FEP performance in OC users and non-users.  A 
recent fMRI study of FEP performance reported differences in the eye movements of OC 
users and non-users, which may represent differences in FEP performance (Mareckova et 
al., 2012).  No behavioral data was provided.  
 
1.5 Rationale for the Present Study 
 In summary, the literature strongly suggests that naturally and pharmacologically 
induced changes in sex hormone levels (estrogen, progesterone, testosterone) are related 
to changes in performance for cognitive measures with established sex differences.  
These include visuospatial measures (mental rotation, spatial orientation) verbal measures 
(verbal fluency, verbal episodic memory) and social cognition measures (facial 
expression processing).  Oral contraceptives alter female hormonal profiles and the 
literature suggests that these changes may contribute to the observed “androgenizing” and 
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“antiandrogenizing” effects of OCs on female cognition.  Currently, the relationship 
between OC use and female cognitive performance remains unclear given that studies 
report conflicting findings and that most studies fail to control for OC formulation and 
the biological androgenicity of OC progestins. 
 The goal of the present study was to examine the relationship between the 
biological androgenicity of oral contraceptives and female cognitive performance by 
exploring highly androgenic OCs, androgenic OCs and the relatively new and less 
studied antiandrogenic OCs.  By exploring antiandrogenic OCs, this study aimed to 
contribute to the sparse literature on biologically antiandrogenic progestins and female 
cognitive performance.  We hoped that findings would help to clarify whether the 
observed trend of antiandrogenized (female-typical) MRT performance in users of 
antiandrogenic OCs is also present on other cognitive measures containing visuospatial 
components as well as other measures where androgenized (male-typical) patterns are 
observed with androgenic formulations.  The present study enriches the OC literature by 
providing data for or against established progestin androgenicity classifications.  For 
example, findings consistent with the study’s hypotheses would lend support to the 
established progestin classifications (i.e., second generation OCs are biologically 
androgenic, fourth generation OCs are biologically antiandrogenic).  Conversely, findings 
that are inconsistent with the study’s hypotheses would lend support to the 
counterargument that all OCs (regardless of progestin generation) are in fact biologically 
hypoandrogenic.  Lastly, the present study aimed to contribute to the OC literature by 
examining female cognitive performance using previously unexplored (matrix reasoning, 
analogical reasoning, facial expression processing) and underexplored (spatial 
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orientation, verbal episodic memory) cognitive measures. Lastly, the present study 
addressed the need to parse out the relationship between OC progestins and cognitive 
performance by clarifying whether or not (and which) OCs have “androgenizing” effects 
on female cognition.    
 
1.6 Aims and Hypotheses of the Present Study 
Aim 1: To investigate the effect of OC progestin androgenicity on participants’ 
performance on measures containing visuospatial components – the Penn Line 
Orientation Test (PLOT) and the Penn Matrix Reasoning Test (PMAT).   
 Hypothesis 1 
 Based on previous research, it was hypothesized that participants using OCs with 
higher levels of androgens (i.e., highly androgenic, androgenic) would exhibit more 
accurate performance than those using OCs with lower levels of androgens (i.e., 
antiandrogenic) and controls on the PLOT and the PMAT.  More specifically, it was 
hypothesized that participants in the highly androgenic and androgenic groups would 
perform similarly to each other.  Further, the highly androgenic and androgenic groups 
would perform better than controls, who would perform better than the antiandrogenic 
group on the PLOT and the PMAT.  
 
Aim 2: To investigate the effect of OC progestin androgenicity on participants’ 
performance on measures containing verbal components – the Penn Word Memory Test 
(CPW) and the Short Penn Verbal Reasoning Test (SPVRT). 
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 Hypotheses 2  
 It was hypothesized that controls would exhibit more accurate performance on the 
CPW than participants using OCs.  Furthermore, no differences in performance were 
expected among OC users.   
 Hypothesis 3 
 Given that males tend to outperform females on verbal reasoning measures, it was 
hypothesized that users of highly androgenic and androgenic OCs would outperform 
controls on the SPVRT.  More specifically, it was hypothesized that participants in the 
highly androgenic and androgenic groups would perform similarly to each other. 
Furthermore, controls were expected to outperform users of antiandrogenic OCs on this 
task. 
 
Aim 3: To investigate the effect of OC progestin androgenicity on participants’ 
performance on measures containing facial expression processing (FEP) components – 
the Penn Emotion Recognition Task (ER40) and the Measured Emotion Differentiation 
Test (MEDF). 
  Hypothesis 4 
 It was hypothesized that users of antiandrogenic OCs would perform more 
accurately than controls, who would perform more accurately than users of highly 
androgenic and androgenic OCs on the ER40 and the MEDF.  More specifically, it was 
hypothesized that, compared to user of highly androgenic and androgenic OCs, users of 
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antiandrogenic OCs and controls would exhibit more accurate performance for anger 






















  26 
CHAPTER 2: METHODS 
2.1 Procedures  
 Participant data were obtained from the Philadelphia Neurodevelopmental Cohort 
Database (PNC) gathered from a large collaborative study between the Center for 
Applied Genomics at Children’s Hospital of Philadelphia (CHOP) and the Brain 
Behavior Laboratory at the University of Pennsylvania (PENN).  The study from which 
the data were obtained, recruited and tested 9,498 youths ages 8-21 years from the greater 
Philadelphia area who attended CHOP or CHOP-affiliated clinics and volunteered to 
participate in genomic studies (Gur et al., 2012). 
 Once eligibility was determined, the assessment session was scheduled to occur 
either at home, in the laboratory, or in the community (e.g., quiet room at a public 
library).  Participants met with a trained research coordinator who explained the research 
procedure and obtained informed consent.  Participants then completed a structured 
clinical interview (GOASSESS) where treatment history including medication use was 
obtained and entered directly into an interface on the coordinator’s Macbook Pro laptop 
computer.  
 For the testing part of the study, the research coordinator maintained standardized 
testing procedures by sitting at the table next to the participant and reading the testing 
instructions as they appeared on the computer screen.  A professional testing environment 
was maintained by minimizing potential distractors (e.g., cell phones, TV).  Using the 
coordinator’s laptop computer, participants completed a 1-hour computerized 
neurocognitive battery (CNB) developed by the University of Pennsylvania (Gur et al., 
2001, 2010) containing 12 tests from a sampling of cognitive domains.  The tests were 
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administered in the following fixed order designed to maintain participant’s engagement 
and reduce fatigue: reading test, motor praxis, emotion identification, continuous 
performance, face memory, word memory, working memory, conditional exclusion, 
emotion differentiation, finger taping, matrix reasoning, spatial memory, verbal 
reasoning, age differentiation, and line orientation.  A subset of the tests was of interest to 
the current study (See Table 1).    
 
 2.1.1 Data Consolidation  
 Data for the present study was provided by PENN and was organized and 
analyzed by this study’s investigator.  Participants’ performance on the standardized 
reading test (WRAT4) was provided as standardized scores and raw scores.  Standardized 
scores were used in lieu of raw scores.  Participants’ performance on the measures of 
interest was provided as both raw scores and age-based normative values.  Because 
participants were administered one of multiple versions of the measures of interest, with 
either the same number (CPW, SPVRT, ER40) or a different number (PLOT, PMAT, 
MEDF) of stimuli, percent correct scores were used in lieu of raw scores.  
 
 2.1.2 Data Consolidation for Oral Contraceptive Status 
 Participants were grouped into one of three OC groups based on their OC’s 
progestin: “highly androgenic” (Levonorgestrel) (n=34), “androgenic” (Norethindrone) 
(n=51) and “antiandrogenic” (Drospirenone) (n=49).  All monophasic antiandrogenic 
OCs contained 3 mg of Drospirenone and all androgenic OCs contained 1 mg of 
Norethindrone (See Table 2).  Initially, there were four types of monophasic highly 
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androgenic OCs: one-month and three-month packs containing 0.15 mg of 
Levonorgestrel and one-month and three-month packs containing 0.10 mg of 
Levonorgestrel.  Because these groups did not significantly differ on demographic 
information or outcome variables of interest, they were collapsed into a single group 
labeled “highly androgenic” OCs (See Figure 2).  
 
 2.1.3 Data Consolidation for Level of Lifetime Depressive Symptoms 
 Participant data included level of lifetime depressive symptoms endorsed at time 
of study participation: no depressive symptoms, one or more depressive symptoms, 
subthreshold depressive disorder (falling short of minimal DSM-IV criteria), threshold 
depression (reporting no distress or impairment but otherwise meeting DSM-IV criteria) 
and depression with significant impairment/distress.  For the purposes of the present 
study level of depressive symptoms were grouped as follows: “no depressive symptoms,” 
“mild/moderate depressive symptoms,” (one of more symptoms and subthreshold 
depression), and “severe depressive symptoms” (threshold depression and depression 
with significant impairment/distress). 
 
2.2 Participants 
 A subset of one hundred and seventy nine participants from the PNC database 
were included in the present study.  Participants were English-speaking females between 
the ages of 15 and 21 years (M =17.94, SD = 1.53) who reported using monophasic OCs 
containing the progestins Levonorgestrel, Norethindrone or Drospirenone (see Table 2) 
or who reported not using any kind of hormonal contraceptive at the time of study 
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participation.  Participants were excluded from the study if they reported a serious birth 
defect or major illness affecting the central nervous system (e.g., epilepsy, 
hydrocephalus, brain tumor, brain damage, meningitis), endocrine disorders 
(hypothyroidism, Congenital Adrenal Hyperplasia (CAH)), major health conditions (e.g., 
Leukemia, HIV, AIDs) and developmental conditions (e.g., Autism, Down’s Sydrome, 
Turner’s Syndrome).  Additionally, participants were excluded from the study if they 
reported taking prenatal vitamins, as this could be an indication of possible pregnancy 
during study participation. 
 The sample included 147 Caucasian (82.1%), 13 African American (7.3 %) and 
19 multi-race participants (19%).  One hundred sixty six participants identified 
themselves as non-Hispanic (92.7%) and 13 participants identified themselves as 
Hispanic/Latino (7.3%).  Participants’ level of education ranged from 7 to 16 years with a 
mean of 11.68 (SD = 1.60).  Parental education was on average 14.70 years (SD = 2.24) 
for mothers and 14.66 (SD = 2.66) for fathers.  Participants’ word reading ability was in 
the average range for age (M = 103.94, SD = 12.81).  Eighty-one participants (45.3 %) 
were identified as having “no depressive symptoms,” 38 participants (21.2%) were 
identified as having “mild/moderate depressive symptoms,” and 60 participants (33.5%) 
were identified as having “severe depressive symptoms.”  Table 3 displays the 
demographic characteristics of the study sample stratified by group.  As previously 
explained, participants who reported taking OCs of interest to the present study were 
grouped into one of three OC groups: “highly androgenic OCs” (n= 34), “androgenic 
OCs” (n=51), and “antantiandrogenic” OCs (n=49).   
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 Participants who reported not taking any kind of hormonal contraceptive at the 
time of the study were grouped into the control group.  Because there were substantially 
greater participants that met criteria for the control group than the OC groups, a subset of 
45 participants meeting criteria for controls, were ultimately included in this study.  
Controls were selected for inclusion in this study using a random-number table and were 
matched to participants in the OC groups on age, race, ethnicity, medical history, 
psychiatric history, lifetime history of depression, education level, mother’s education, 
father’s education, and word reading performance (See Table 3). 
 
2.3 Measures  
 2.3.1 Demographic Information   
 Demographic information was collected by PENN for each participant using a 
Demographics Questionnaire and a structured clinical interview (i.e., GOASSESS).  The 
following information was obtained: age, sex, race, ethnicity, current medications, 
medical history, psychiatric history, and current level of depressive symptoms. 
 
 2.3.2 Standardized Reading Test  
 A brief (i.e., approximately 3 minutes) standardized reading test from the Wide 
Range Achievement Test (WRAT4, Wilkinson & Robertson, 2006) was administered by 
PENN to provide an estimate of IQ and determine participants’ ability to complete the 
Computerized Neurocognitive Battery (CNB).  
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 2.3.3 Computerized Neurocognitive Measures 
 The measures included in the present study were part of a 1-hour computerized 
neurocognitive battery (CNB) administered to participants as part of the collaborative 
study between CHOP and PENN.  The CNB consisted of 14 tests assessing five 
neurobehavioral functions, among them episodic memory (e.g., CPW), complex 
cognition (e.g., sPVRT, PMAT, PLOT), and social cognition (ER40, MEDF) (Gur et al., 
2012).  
 
 Penn Line Orientation Test (PLOT) (Gur et al., 2012) 
 The PLOT was included as a measure of participants’ spatial orientation 
performance.  The PLOT is a short (i.e., approximately 5 minutes) computerized measure 
of spatial orientation inspired by Benton’s Judgment of Line Orientation test (Benton et 
al., 1978).  The PLOT contains either 12 or 24 trials in which participants are shown a 
pair of lines with different orientations; one red (fixed) and the other blue (moveable).  
Participants are asked to rotate the blue line by clicking on one of two buttons that rotate 
the line by 3, 6, or 9 degrees (depending on the item) either clockwise or 
counterclockwise.  Throughout the test, there are variations in the length of the blue line 
(long or short), possible degree of movement in each click, and relative location of both 
lines on the screen.  Scores are provided for total correct trials as well as broken down by 
blue line length, possible degree per click, and for each of the four possible relative line 
positions.  In a recent study by Gur and colleagues (2012) involving a subset of the 
participants from the PNC from which the current participants were drawn, the PLOT 
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demonstrated sensitivity to sex differences, with males outperforming females overall (p 
< .0001, ES = - 0.23) and in the 18 through 21 age groups (Gur et al., 2012).  Overall 
task accuracy (% correct) and reaction time (ms) were the variables of interest for the 
current study.   
  
 Penn Matrix Reasoning Test (PMAT) (Gur et al., 2012) 
 The PMAT was developed as a measure of a nonverbal reasoning.  Given the 
spatial components of the task, it is used in this study as a measure of visuospatial 
performance.  The PMAT is a short (i.e., approximately 5 minutes) computerized version 
of the Raven’s Progressive Matrices (Raven, 1960) which measures abstraction and 
mental flexibility.  The PMAT is a multiple-choice test that requires participants to 
reason by geometric analogy and conceptualizing design, and numerical relationships.  
Questions range in difficulty from very easy to increasingly complex.  Participants are 
presented with patterns made up of 2X2, 3X3, and 1X5 arrangements and are asked to 
click on the square that best fits the missing square of the pattern.  Each question has 5 
response choices and the measure contains either 18 or 24 questions and 3 adaptive bonus 
questions based on the participant’s performance.  The questions are presented in order of 
increasing difficulty and the test is discontinued after 5 incorrect responses (to any 5 
items) at which point the 3 bonus questions are presented.  The final score represents the 
total number of correct responses.  In the recent PNC study by Gur and colleagues (2012) 
the PMAT showed sensitivity to sex differences, with males outperforming females 
overall (p = .0059, ES = - 0.04) and with males showing better accuracy in the 18 
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through 21 age groups (Gur et al., 2012).  Overall task accuracy (% correct) and reaction 
time (ms) were the variables of interest for the current study.  
 
 Short Penn Verbal Reasoning Test (sPVRT) (Gur et al., 2010) 
 The sPVRT was used as a measure of participants’ verbal reasoning.  The sPVRT 
is a short (i.e., approximately 2.5 minutes) computerized measure of verbal reasoning by 
analogy.  It consists of 15 multiple choice verbal analogy problems from the Educational 
Testing Service (ETS) factor-referenced test kit.  The final score represents the total 
number of correct responses. The sPVRT was shortened from an earlier version (Penn 
Verbal Reasoning Test (PVRT)) containing 30 multiple-choice analogies (Gur, Gur, 
Obrist, Skolnick, & Reivich, 1987), which was found to be sensitive to sex differences 
(Gur et al., 2001).  The sPVRT has demonstrated high internal consistency (Cronbach‘s α 
= .90) and sensitivity to sex differences (Gur et al., 2010).  In the recent PNC study by 
Gur and colleagues (2012) the sPVRT showed sensitivity to sex differences, with males 
outperforming females overall (p = .0111, ES = - 0.02) and with males showing better 
accuracy in the 18 to 19 age group (Gur et al., 2012).   Overall task accuracy (% correct) 
was the variable of interest for the current study.  
 
 Penn Word Memory Test (CPW) (Gur et al., 1993) 
 The CPW was used as a measure of participants’ verbal episodic memory.  The 
CPW is a short (i.e., approximately 3 minutes) computerized measure of word memory.  
The CPW requires participants to memorize 20 target words, which are presented one a 
time at the rate of one word per second.  Participants are then shown a series of words 
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(one a time) containing the 20 target words mixed with 20 novel foils equated for 
frequency, length, concreteness and imageability.  Participants are then asked to decide 
whether they have seen the word before by clicking on 1 of 4 buttons presented at the 
bottom of the screen: “definitely yes”, “probably yes”, “probably no” and “definitely no”.  
The CPW is scored based on the number of correct and incorrect responses, divided into 
true/false positives/negatives.  The CPW has demonstrated high internal consistency 
(Cronbach‘s α = .90) (Gur et al., 2010) and sensitivity to sex differences favoring females 
(Gur et al., 2001; Gur et al., 2010).   In the recent PNC investigation by Gur and 
colleagues (2012) the CPW showed sensitivity to sex differences favoring females (p = 
.0268, ES = 0.13), with females showing more accurate performance in the 20 to 21 age 
group (Gur et al., 2012).  Overall task accuracy (% correct) and reaction time (ms) were 
the variables of interest for the current study.  
 
 Penn Emotion Recognition Task (ER40) (Gur et al., 2010) 
 The ER40 was used as a measure of participants’ emotion recognition. The ER40 
is a short (i.e., approximately 2.5 mintues) computerized measure of facial 
expression/affect identification.  In the ER40 participants are shown 40 color photographs 
of faces balanced for sex, age, and ethnicity.  There are four female faces and four male 
faces for each emotion.  The faces are presented one at a time and participants are asked 
to determine what emotion each face is showing from a multiple choice format: “anger,” 
“fear,” “happiness,” “sadness,” or “no feeling.”  Scores are based on the number of total 
correct identifications including correct responses for male versus female faces, correct 
responses per emotion and false positives per emotion.  The ER40 has demonstrated high 
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internal consistency (Cronbach‘s α = .92) and sensitivity to sex differences favoring 
females (Gur et al., 2010).  In the Gur and colleagues (2012) PNC investigation, the 
ER40 showed sensitivity to sex differences with females outperforming males overall (p 
< .0001, ES = 0.25) however, no significant sex differences were reported in the 18 
through 21 age groups (Gur et al., 2012).  Overall task accuracy (% correct) and reaction 
time (ms) were the variables of interest for the current study.  
 
 Measured Emotion Differentiation Test (MEDF) (Gur et al., 2012) 
 The MEDF was used as a measure of participants’ emotion intensity 
differentiation.  The MEDF is a short computerized measure of facial expression/emotion 
differentiation  (administration time: M = 3.1 minutes, SD = 0.8).  In the MEDF, 
participants are presented with a pair of images of the same individual expressing the 
same emotion (“anger,” “fear,” “happiness,” “sadness”), one more intense than the other 
or of equal intensity.  The participant is then asked to click on the face that displays the 
more intense emotion or indicate whether both images have equal intensity.  The 
MEDF36 consists of either 36 or 60 random untimed trials, some showing no emotional 
difference and most showing emotional differences in increments of 10% ranging from 
10% to 60%.  Scores are based on the number of correct responses.  In the PNC study by 
Gur and colleagues (2012) the ER40 showed sensitivity to sex differences with females 
outperforming males overall (p < .0001, ES = 0.25) however, no significant sex 
differences were reported in the 18 through 21 age groups (Gur et al., 2012).  Overall task 
accuracy (% correct) and reaction time (ms) were the variables of interest for the current 
study.  
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CHAPTER 3: RESULTS 
3.1 Demographic Analyses 
 Demographic analyses were conducted in order to determine if there were any 
pre-existing differences among the groups that would need to be controlled for in 
subsequent analyses.  Chi Square analyses revealed no significant differences between 
groups on race, ethnicity, medical history, psychiatric history and level of depressive 
symptoms.  One-way ANOVAs revealed no significant differences between the groups 
on age, education, or reading test performance (WRAT4). 
 
 3.1.1 Age as a Possible Covariate 
 Previous research using the Philadelphia Neurodevelopmental Cohort Database 
(PNC) from which these data were obtained suggests that age is significantly correlated 
with performance accuracy on the measures of interest (Gur et al., 2012).  Therefore, in 
the present study age was carefully considered as a possible confounding factor.  To 
investigate the relationship between age and the outcome variables, bi-variate 
correlations were conducted.  Age was significantly correlated with participants’ 
performance on the PLOT (r =.21, p = .006), the PMAT (r = .27, p < .001), and the 
SPVRT (r = .16, p = .035).  Due to these significant relationships, age was further 
investigated as a possible covariate.  First, one-way ANOVAs were performed to 
examine possible differences in PLOT, PMAT, and SPVRT performance across groups.   
Results revealed no significant differences among groups on the PLOT (F(3,175) = 0.11, 
p =.954, partial η2 =.002), the PMAT (F(3,175) = 1.33, p =.267, partial η2 =.022) or the 
SPVRT (F(3,175) = 1.29, p =.280, partial η2 =.022). 
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Then, ANCOVAs were performed for each of these outcome variables to investigate the 
impact of OC androgenicity while controlling for age.  Results of these ANCOVAs 
revealed that age was not a covariate as group status continued to not be a significant 
predictor of outcome variables.   
 Given that age did not significantly alter the relationship between OC status and 
the outcome variables, subsequent analyses were conducted using percent correct scores 
rather than age-based normative values.  Although previous PNC studies used aged-based 
normative values in their analyses (Gur et al., 2010; Gur et al., 2012), percent correct 
scores were better suited for the present study.  First, available age-based normative 
values were derived from both male and female participants and the present study was 
interested in female performance only.  Furthermore, normative scores were only 
available for overall performance accuracy and the present study was interested in anger 
performance accuracy on the ER40 and the MEDF. 
  
 3.1.2 Depressive Symptoms as a Possible Covariate 
 Given that the rate of lifetime severe depressive symptoms in this sample was 
much higher (33.5%) than what would be expected in the general population of 17-18 
year old adolescents (15.4%) (Merikangas et al., 2010), depressive symptoms were 
examined as a possible confounding factor.  First, separate one-way ANOVAs were 
performed to examine performance on outcome variables across levels of depressive 
symptoms.  Results revealed that participants’ ability to correctly identify intensity of 
anger faces on the MEDF differed based on level of depressive symptoms (F(2,176) = 
3.87, p =.023, partial η2 =.042).  However, a subsequent 3X4 factorial ANOVA did not 
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reveal a significant interaction between group status and level of depressive symptoms, 
suggesting that level of depressive symptoms was not a significant covariate (F(6,178) = 
.59, p = .738, partial η2 =.021).  Therefore, level of depressive symptoms was not 
included as a factor in subsequent analyses. 
 
3.2 Hypothesis 1 
  The first aim of this study was to investigate the effect of OC progestin 
androgenicity on participants’ performance on measures containing visuospatial 
components.  Hypothesis 1 stated that the “highly androgenic” OC group and the 
“androgenic” OC group would perform more accurately than controls, who would 
perform more accurately than the “antiandrogenic” OC group on outcome measures 
containing visuospatial components (PLOT, PMAT).  Descriptive statistics for the PLOT 
and the PMAT are summarized in Table 4.  To examine the effects of OC androgenicity 
on visuospatial performance, a series of one-way ANOVA were conducted using PLOT 
and PMAT total percent accuracy as dependent variables.  Results indicated that scores 
on the PLOT did not significantly differ among groups (F(2,178) = .11, p = .954, partial 
η2 =.002).  Similarly, scores on the PMAT did not significantly differ among groups 
(F(2,178) = 1.33, p = .267, partial η2 =.022).  
 
3.3 Hypothesis 2  
 The second aim of this study was to investigate the effect of OC progestin 
androgenicity on participants’ performance on measures containing verbal components.  
Hypothesis 2 stated that controls would perform more accurately than all OC groups on 
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the CPW. Descriptive statistics for the CPW are summarized on Table 4.  To examine the 
effects of OC androgenicity on CPW performance, a one-way ANOVA was conducted 
using total percent accuracy as the dependent variable.  Results indicated that scores on 
the CPW did not significantly differ among groups (F(2,178) = .71, p = .551, partial η2 
=.012). 
 
3.4 Hypothesis 3 
 Related to Aim 2, hypothesis 3 stated that the “highly androgenic” OC group and 
the “androgenic” OC group would perform more accurately than controls, who would 
perform more accurately than the “antiandrogenic” OC group on the SPVRT.  
Descriptive statistics for the SPVRT are summarized on Table 4.  To examine the effects 
of OC androgenicity on SPVRT performance, a one-way ANOVA was conducted using 
total percent accuracy as the dependent variable.  Results indicated that scores on the 
SPVRT did not significantly differ among groups (F(2,178) = 1.29, p = .280, partial η2 
=.022).  However, although the difference among groups was not significant, the pattern 
of mean scores was generally consistent with the hypothesis. 
 
3.5 Hypothesis 4 
 The third aim of this study was to investigate the effect of OC progestin 
androgenicity on participants’ performance on measures containing FEP components.  
Hypothesis 4 stated that the “antiandrogenic” OC group would perform more accurately 
than controls, who would perform more accurately than the “highly androgenic” and the 
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“androgenic” OC groups on outcome measures containing FEP components (ER40, 
MEDF).   
 Given that the ER40 and the MEDF are similar measures of FEP, a one-way 
MANOVA was performed to examine the effect of OC androgenicity on composite FEP 
performance.  Results indicated a statistically significant difference in FEP processing 
among groups, F(6,348) = 2.23, p < .05; Wilk's Λ = 0.927, partial η2 =.037).  To follow 
up, univariate one-way ANOVAs were conducted using ER40 and MEDF total percent 
accuracy as separate dependent variables.  Results indicated that differences in ER40 
performance accuracy among groups approached significance (F(2,178) = 2.06, p = .107, 
partial η2 =.034).  Similarly, scores on the MEDF approached significance (F(2,178) = 
2.46, p = .064, partial η2 =.040).  Given the exploratory nature of this study, p values 
between .06 and .10 were considered borderline significant and further examined.  Post 
hoc comparisons using Tukey’s HSD indicated no significant differences between groups 
on ER40 performance.  However on the MEDF, participants in the “highly androgenic” 
OC group (M = 81.85, SD = 8.21) significantly outperformed participants in the control 
group (M = 77.05, SD = 8.25), p < .05 (See Table 4). 
 Related to hypothesis 4, we expected that “antiandrogenic” OC group and 
controls would perform more accurately than the “highly androgenic” and the 
“androgenic” OC groups for anger faces on the ER40 and the MEDF.  To examine the 
effects of OC androgenicity on anger performance, additional one-way ANOVAs were 
conducted using ER40 and MEDF anger percent accuracy as dependent variables.  
Results indicated that anger scores did not significantly differ among groups on the ER40 
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(F(2,178) = 1.35, p = .259, partial η2 =.023) or the MEDF (F(2,178) = .83, p = .480, 
partial η2 =.014).  
 
3.6 Power  
 A power analysis using the guidelines set forth by Cohen (1992) indicated that 
this study was adequately powered to detect a medium effect size of d = .25 for a one-
way ANOVA with 4 groups, α = .05, power = .80.  The intended sample size for the 
study was a total 180 participants; 45 participants per group.  The actual sample size was 
179 participants; 45 controls, 49 “antiandrogenic” OC users, 51 “androgenic” OC users, 
and 34 “highly androgenic” OC users.  Given the study’s marginally significant findings 
with small to moderate effect sizes, OCs appear to have generally small effects on female 
neurocognitive performance.  In order to detect these small effect sizes, a sample size of 
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CHAPTER 4: DISCUSSION 
 The goal of this study was to examine the relationship between OC progestin 
androgenicity and female performance on measures with visuospatial (PLOT, PMAT), 
verbal (CPW, SPVRT) and facial expression processing (ER40, MEDF) components.  
Findings revealed a marginally significant trend of FEP performance differences across 
groups, specifically that participants using “highly androgenic” OCs were more accurate 
at determining facial expression intensity on the MEDF than naturally cycling controls.   
However, the current study failed to reveal a significant relationship between OC 
androgenicity and female performance on measures containing visuospatial and verbal 
components.  
 
4.1 Review of Findings 
 4.1.1 Facial Expression Processing Performance 
 Based on previous findings of a female advantage on computerized measures of 
emotion recognition (Gur et al., 2010; Gur et al., 2012; Montagne et al., 2005) and 
decreased FEP accuracy in females after testosterone administration (Van Honk et al., 
2007), it was expected that OC androgenicity would hinder performance on measures 
with FEP components.  Furthermore, we expected decreased performance accuracy for 
anger faces with androgenic OCs (“highly androgenic”, “androgenic”) given previous 
findings of decreased accuracy at labeling anger facial expressions in males compared to 
females (Hampson et al., 2006; Montagne et al., 2005) and in females after a single dose 
of testosterone (Van Honk et al., 2007).  This was the first study to examine OC 
androgenicity and female FEP performance both overall and specifically for anger faces. 
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 Although there was a significant among-groups difference in performance 
accuracy on composite ER40 and MEDF performance, analyses of the individual 
measures revealed marginally significant findings.  Our hypothesis of hindered FEP 
performance with OC androgenicity was unsupported.  On the contrary, findings revealed 
that “highly androgenic” OC users performed more accurately than naturally cycling 
controls on the MEDF.  
 Although the unexpected finding that “highly androgenic” OC users outperformed 
controls may be spurious, we entertain the notion that it may be consistent with past 
findings of increased FEP performance with lower sex hormone levels.  Contrary to 
established parameters of OC androgenicity, some researchers argue that OCs lower all 
natural sex hormones and therefore have no clinically meaningful androgenic effects on 
cognition (Stanczyk, 2003; Thorneycroft et al., 1999).  This argument is supported by a 
recent meta-analysis showing that OCs significantly suppress natural testosterone levels 
regardless of progestin generation (Zimmerman, Eijkemans, Coelingh Bennink, 
Blankenstein & Fauser, 2014).  
 Following this argument, we could speculate that the OC users in our sample had 
lower sex hormone levels than naturally cycling controls.  As such, our study’s finding 
and pattern of mean scores on the MEDF are consistent with previous research showing 
increased FEP performance with lower estrogen and progesterone levels (i.e., follicular 
phase) (Guapo et al., 2009; Derntl et al., 2008a; Derntl et al., 2008b; Derntl et al., 2013). 
 Our finding however, cannot fully support a position that OCs in general facilitate 
FEP performance by lowering natural sex hormones as only “highly androgenic” OC 
users outperformed naturally cycling controls on the MEDF.  Progestin androgenicity 
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does not fully account for these findings either otherwise both androgenic OC groups 
(“highly androgenic” and “androgenic”) would have outperformed controls on the 
MEDF.  Given that the major ingredient difference among the OCs used in the present 
study was progestin type (all OCs had comparable doses of ethinyl estradiol) suggests 
further exploration of another progestin effect - progestogenicity.  Whereas the scope of 
the present study was progestin androgenicity, it should be noted that the OC progestins 
investigated (Levonorgestrel, Norethindrone, Drospirenone) have varying levels of 
progestogenicity.  A progestin’s progestogenicity is measured by its relative binding 
affinity (RBA) to progesterone receptors in the body and central nervous system.  
Compared to natural progesterone, Levornogestrel has a progestogenic RBA of 150%, 
Norethindrone 75% and Drospirenone 35% (Schindler, et al., 2008).  Because of 
differences in progestogenicity, Levornogestrel may be used in much smaller dosages 
(i.e., 0.10 – 0.15 mg) to obtain a progestogenic effect equivalent to that of Norethindrone 
(i.e., 1 mg) and Drospirenone (i.e., 3 mg) (Greet et al., 2005).  Nonetheless, the OC 
progestins included in the present study are derived from different chemical compounds, 
which may differentially influence FEP performance accuracy.  Given the complex 
biological effects of OC progestins (i.e., androgenicity, progestogenicity) and the lack of 
research into OC progestogenicity and female cognition, we cannot interpret participants’ 
MEDF performance beyond stating that progestogenicity may have played a role. 
 As previously discussed, performance differences among groups was only 
observed on the measure of facial emotion intensity (MEDF) but not on the measure of 
emotion recognition (ER40).  Furthermore, the pattern of mean scores on the ER40 did 
not reveal a similar relationship (i.e., naturally cycling controls were more accurate than 
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“antiandrogenic” OC users).  One way to account for these findings is to conjecture that 
the MEDF may be more sensitive than the ER40 at detecting differences in performance 
accuracy related to sex hormone fluctuations.  
 The ER40 and the MEDF were designed to measure emotion recognition and 
emotion intensity differentiation respectively.  The primary difference between these 
measures lies in the emotional stimuli presented.  The ER40 contains images of full-
blown emotions (100% intensity) whereas the MEDF contains images with varying levels 
of emotion intensity (i.e., 0% - 60% difference).  Interestingly, our findings of 
performance differences on the MEDF but not the ER40 parallel previous findings of sex 
differences in emotion recognition.  A series of FEP studies by Hoffman et al. (2010) 
reported that females were more accurate than males at recognizing subtle facial 
emotions but both sexes were equally accurate when full-blown emotions were presented 
(i.e., 100% intensity).  Hoffman and colleagues argued that the female FEP advantage 
may be mediated by their ability to recognize facial emotions under conditions of subtle 
emotional information (Hoffman et al., 2010).  This, they argued, explains why meta-
analyses of FEP studies showing a female advantage on average report considerably 
small effect sizes and why some studies fail to detect sex differences in FEP performance 
altogether (Hoffman et al., 2010).  Given that the present study identified between-group 
differences on the MEDF but not on the ER40 and with a slightly larger small-moderate 
effect size on the MEDF than the ER40 suggests that sex hormone alterations (i.e., via 
OC use) may affect a woman’s ability to interpret subtle facial expressions but may not 
hinder overall emotion recognition accuracy.  
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 Lastly, our hypothesis of hindered facial anger accuracy with OC androgenicity 
was not supported nor were the pattern of mean scores on both measures consistent with 
the study’s hypothesis. There were no significant differences in emotion recognition of 
facial anger (ER40) or emotion intensity differentiation of facial anger (MEDF).  
Interestingly, the pattern of mean scores on each measure was contradictory as naturally 
cycling controls recognized anger faces more accurately than OC users on the ER40 and 
less accurately than OC users on the MEDF.  As previously discussed, the MEDF may be 
more sensitive than the ER40 at picking up performance differences related to hormone 
fluctuations.  Although these differences may be spurious, considering MEDF anger 
performance patterns more representative of FEP changes with OC use would lend 
additional support to arguments against established OC androgenicity parameters. 
Increased anger sensitivity with OC use would support theories that OC users have lower 
natural testosterone levels than naturally cycling females.  
 Multiple explanations may account for our lack of significant findings.  First, 
some facial expressions (i.e., disgust) may be affected by sex hormone changes more than 
others (i.e., anger).  Whereas two FEP studies to date have reported a female advantage 
for subtle disgust facial expressions (Hoffman et al., 2010; Montagne et al., 2005), only 
one of those studies reported a female advantage for subtle anger facial expressions 
(Montagne et al., 2005).  The second study to replicate significant performance 
differences for anger expressions among females achieved this after administering a dose 
of sublingual testosterone shown to increase female testosterone levels to male-like levels 
(Van Honk et al., 2007).  These findings suggest that in females, anger FEP performance 
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may be sensitive to much higher testosterone thresholds (i.e., male-like levels) than any 
afforded by the androgenic effects of OC progestins.  
 
 4.1.2 Visuospatial Performance 
 Based on the hypothesis that OC androgenicity would facilitate visuospatial 
performance, it was expected that users of “highly androgenic” and “androgenic” OCs 
would perform more accurately on measures with visuospatial components.  Furthermore, 
we expected to see decreased performance accuracy on users of “antiandrogenic” OCs 
based on previous research showing hindered spatial rotation performance with 
antiandrogenic OCs (Griksiene & Ruksensas, 2011, Wharton et al., 2008).  
 Our hypotheses were largely unsupported.  There were no differences in 
visuospatial performance between OC users and non-users.  Although female spatial 
orientation has been examined within the context of OC use (Goyette et al., 2010), this 
was the first study to control for OC progestin androgenicity.  Consistent with Goyette 
and colleagues’ findings (2011), this study did not observe differences in spatial 
orientation performance between naturally cycling females and OC users.  
 Similarly, despite the geometric components of the PMAT, no relationship 
between OC androgenicity and performance accuracy was observed.  This is the first 
study to date, to examine female matrix reasoning performance and OC androgenicity. 
 Given that most studies reporting significant visuospatial performance differences 
in OC users employ a mental rotation task (MRT) suggests that some aspects of 
visuospatial processing (i.e., spatial rotation) may be more sensitive to hormonal 
fluctuations than others (i.e., spatial orientation, reasoning by geometric analogy).  
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 4.1.3 Verbal Performance 
 Based on previous findings of females outperforming males on verbal episodic 
memory tasks (Gur et al., 2001; Temple & Cornish, 1993; Zelinski et al., 1993), it was 
expected that non-OC users would outperform OC users on the CPW.  
 Despite a lack of significance, findings were consistent with previous research 
reporting no differences in the verbal episodic memory of OC users and naturally cycling 
controls (Wharton et al., 2008). 
 Based on previous findings of males outperforming females on measures of 
verbal reasoning by analogy (Lim, 1994; Gur et al., 2012), it was expected that OC 
androgenicity would facilitate verbal reasoning performance.  It was hypothesized that 
users of “highly androgenic” and “androgenic” OCs would exhibit more accurate verbal 
reasoning performance than controls who were expected to perform more accurately than 
users of  “antiandrogenic” OCs. No study to date had examined female analogical 
reasoning and androgenicity. 
 Our hypothesis was unsupported however; the pattern of mean scores was 
generally consistent with the hypothesis of a negative relationship between OC 
androgenicity and female verbal analogical reasoning.  An examination of effect sizes 
revealed a small effect size, suggesting that the effects of OC androgenicity on analogical 
reasonins are not clinically significant. 
 Given that most studies reporting verbal performance differences in females with 
sex hormone changes use a verbal fluency measure suggests that some aspects of verbal 
processing (i.e., verbal fluency) may be more sensitive to hormonal fluctuations than 
others (verbal episodic memory, analogical reasoning).  
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4.2 Limitations 
 Several of the study’s limitations stem from using a pre-existing data set. 
 First, using a database limited the study to a quasi-experimental design, as participants 
could not be randomly assigned to their respective groups.  Therefore, although the 
groups were relatively equal in demographic information, the investigator could not 
account for any pre-existing differences that may have led participants to choose an 
“androgenic” OC versus an “antiandrogenic” one.  Oral contraceptives were primarily 
designed for pregnancy prevention however they may be prescribed for noncontraceptive 
reasons.  Common “off-label” indications of OCs include the treatment of menstrual 
disorders (e.g., dysmenorrhea, amenorrhea, irregular cycles, excessive bleeding), 
hyperandrogenic disorders (e.g., acne, hirsutism), and gynecological conditions like 
endometriosis and polycystic ovary syndrome (Dayal & Barnhart, 2001).  Additionally, 
several consumer-related factors may affect the OC formulations or brand females use.  
For example, one female may choose “antiandrogenic” 24/4 formulation OC Yaz over a 
typical 21/7 formulation OC because Yaz will result in shorter menstrual periods whereas 
another female may choose Yaz because studies show that Drospirenone-containing OCs 
result in less weight gain and water retention (Bonnema & Spencer, 2011).  Similarly, 
most of the females that choose extended cycle (3-month) “highly androgenic” OCs like 
Seasonale do so because of the convenience of having fewer menstrual periods however, 
a large number of females avoid extended cycle OCs because of the common 
misconception that bleeding once a month is “necessary” and “normal” (Andrist et al., 
2004).  Cost can also be a determining factor as some OC brands may require higher 
copays and some formulations (i.e. 3-month packs) may require users to pay 3-months’ 
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worth of copayments up-front.  Lastly, other variables like media advertisements and the 
availability of OC samples at clinics and gynecologists’ offices (which may or may not 
be driven by pharmaceutical companies) should also be explored. 
 The present study was also limited in that there were no available data from which 
to directly measure or estimate participants’ hormonal status.  No information was 
obtained regarding OC use therefore OC group assignment was solely based on alleged 
progestin androgenicitiy.  Because the biological androgenicity of OC progestins was not 
verified via hormonal assays, the investigator could not ascertain whether in fact a 
participant was truly in the “highly androgenic” versus the “androgenic” hormone range.  
Similarly, the study did not obtain information to estimate the cycle phase controls, 
potentially mixing together women with very different hormonal profiles (e.g., low 
hormone women in the follicular phase and high hormone women during the luteal 
phase).  
 Additional limitations included that the OC group showing a nearly significant 
trend on the MEDF (“highly androgenic”) contained the smallest number of participants 
and that the study’s sample may have not have been representative as participants 
reported higher rates of lifetime depressive symptoms than those found in the general 
population.  
4.3 Directions for Future Research 
 4.3.1 Study Design 
 Future investigations of the relationship between OC androgenicity and female 
neurocognitive performance may benefit from following a true experimental design in 
which neurocognitive performance is assessed before and after random assignment to an 
  51 
OC group.  Future studies should examine participants’ estrogen, progesterone and 
testosterone levels via hormonal assays before grouping OC users into androgenicity 
categories.  Additionally, historical information regarding OC use (e.g., why OCs were 
prescribed, why the specific OC brand was chosen, length of use, etc) should be obtained 
in an effort to uncover any pre-existing differences among different OC users that may 
contribute to neurocognitive performance differences.  
  
 4.3.2 Further Exploration of Depression and Oral Contraceptives 
 Although depression was beyond the scope of the present study and was not 
found to be a significant factor in participants’ neurocognitive performance, it remains a 
variable of interest given the higher prevalence of lifetime depressive symptoms in OC 
users compared to controls.  Of specific concern was the possibility that other variables 
related to depression may have played a role in participants’ performance.  
 Early studies of OCs and depression concluded that depression was a side effect 
of OC use (Herzberg, Johnson, & Brown, 1970) however, recent population-based 
studies report either no relationship between OCs and depression (Joffe, Cohen, & 
Harlow, 2003; Duke, Sibbritt, & Young, 2007) or that OCs reduce level of depressive 
symptoms (Toffol, Heikinheimo, Koponen, Luoto, & Partonen, 2011; Keyes et al., 2013).  
The true link between OC use and depression may lie in their relationship to premenstrual 
dysphoric disorder (PMDD) - a severe form of premenstrual syndrome (PMS) 
characterized by emotional symptoms such as irritability, mood swings and depressed 
mood surfacing during the luteal phase of the menstrual cycle and disappearing shortly 
after menstruation (Soares, Cohen, Otto, & Harlow, 2001).  Premenstrual dysphoric 
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disorder (PMDD) and depression share a significant comorbidity (Soares et al., 2001), to 
the extent that PMDD is regarded as a variant of depression and is categorized in the 
DSM-IV as a “depressive disorder not otherwise specified” (Landen & Eriksson, 2003).   
While the role of sex hormones in the etiology of PMDD and depression remains unclear, 
researchers theorize that the sex hormone estrogen may play a role.  Specifically, that 
estrogen may mediate serotonergic functions and therefore precipitous changes in 
estrogen levels may trigger depressive symptoms (Joffe & Cohen, 1998; Keyes et al., 
2013).  Because of their stabilizing effects on sex hormones, OCs have been widely 
prescribed as an off-label treatment of PMDD (Freeman et al., 2001). Newer OCs 
containing the progestin Drospirenone (e.g., Yaz, Yasmin) have even been recognized by 
the FDA as effective treatments of PMDD and have been marketed accordingly 
(Schindler, 2013).  This may in part explain why in the present study, users of 
“antiandrogenic” Drospirenone-based OCs reported the highest levels of severe lifetime 
depressive symptoms. 
 As previously discussed, future studies should gather historical data on why OCs 
(or particular types of OCs) were prescribed as off-label uses like the treatment of PMDD 
may elucidate pre-existing differences among groups which may contribute to 
performance differences.  Additionally, this information would allow researchers to 
create subgroups of OC users based on disorder-driven categories (e.g., PMDD 
treatment), which may help to further clarify the relationship between sex hormones and 
female cognition.  For example, females who were prescribed OCs for PMDD may be 
more cognitively sensitive to sex hormone changes than females who where prescribed 
OCs solely for contraceptive purposes. 
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 4.3.3. Further Exploration of Facial Expression Processing Measures 
 The present study explored female performance on two measures containing FEP 
components – emotion recognition (ER40) and emotion intensity differentiation (MEDF).  
Although findings suggest the MEDF may be more sensitive to hormonal fluctuations 
than the ER40, these measures should be jointly explored as their design may allow for 
further clarification of the potentially moderating role of emotion intensity in facial 
expression recognition.  Additionally, ideally disgust facial expressions would be 
included as previous research has shown differences in FEP performance for disgust 
expressions with hormonal fluctuations.  Lastly, FEP performance for low to mid 
intensity emotions on the MEDF should be examined to determine if there are any 
between-group differences that may have been missed when the total intensities for each 
emotion was assessed.  
 
4.4 Clinical Implications  
 4.4.1 The Role of Emotion Intensity in Facial Expression Processing 
 Various studies report differences in female FEP performance with natural and 
pharamacologically induced hormonal changes.  To date the only study of female FEP 
performance and OC focused on imaging and did not provide behavioral data of 
participants’ performance (Mareckova et al., 2012).  Additionally, the present study was 
the first to research OC androgenicity and FEP performance.  The study’s nearly 
significant trend of performance differences for facial expressions with varying emotion 
intensities (MEDF) but not for full-blown facial emotions (ER40) contributes evidence 
that some aspects of FEP (i.e., emotion intensity differentiation) that may be more 
  54 
sensitive to hormonal fluctuations than others (i.e., emotion recognition).  The study’s 
findings also contribute to a developing theory in the FEP literature that the female FEP 
advantage lies in the processing of subtle facial emotional cues. 
  
 4.4.2 Contributions to the Verbal and Visuospatial Literature 
 The majority of studies examining female cognitive performance and sex 
hormone changes focus on verbal and spatial measures of verbal fluency and spatial 
orientation respectively.  The present study contributes to the existing literature on female 
verbal cognitive performance by replicating previous null findings in verbal episodic 
memory across OC users and controls.  Additionally, it expands the literature by being 
the first study to examine OC use and OC androgenicity and female analogical reasoning.  
Similarly, the present study contributes to the body of research into female visuospatial 
performance by replicating previous null findings in spatial orientation performance 
across OC users and controls and by being the first study to examine OC androgenicity 
and spatial orientation.  Lastly, the present study expands visuospatial processing 
research by examining OC use and OC androgenicity and female matrix reasoning 
performance. 
 
 4.4.3 Cognitive Performance and Progestin Androgenicity Parameters 
 Overall, findings of performance patterns on the MEDF similar to those seen in 
low hormone females contribute behavioral data that supports arguments against 
established OC androgenicity parameters.  Additionally, patterns of mean scores 
inconsistent with either OC androgenicity or hypoandrogenicity arguments, highlight the 
  55 
need to explore the progestational components of oral contraceptives to gain a more in-
depth understanding of the synergistic effects of natural and synthetic sex hormones on 
female cognition.  Lastly, the study’s findings of mostly small effect sizes suggest that 
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Table 1. List of Measures and Variables of Interest 
_____________________________________________________________ 
Domain Measure Variable of Interest 
 
Visuospatial  
  PLOT    Total % Correct (raw) 
  PMAT    Total % Correct (raw) 
  
Verbal  
  sPVRT   Total % Correct (raw) 
  CPW    Total % Correct (raw) 
 
Facial Expression Processing     
  ER40    Total % Correct (raw) 
      Anger % Correct(raw) 
 
  MEDF    Total % Correct (raw) 

















Table 2. List of Oral Contraceptives by Group 
 
________________________________________________________________________ 
 Antiandrogenic                      Androgenic                             Highly Androgenic  
 (n=49)                                    (n=51)                                     (n=34) 
 
Drospirenone                          Norethindrone                           Levonorgestrel  
3 mg                          1 mg                                 .15 mg                   .10 mg                          
 
Yaz                           Loestrin                  Seasonique*          Aviane  
(n=25)                          (n=42)                   (n=11)            (n=7) 
 
Yasmin                                    Junel                               Jolessa*                 Alesse 
(n=10)                                     (n=4)                   (n=3)            (n=3)         
  
Ocella                                      Microgestin                  Seasonale*            Lutera 
(n=9)                          (n=4)                   (n=2)            (n=2) 
          
Gianvi                                     Estrostep                  Levora                   Sronyx                           
(n=4)                                       (n=1)                                (n=2)            (n=1)  
 
Beyaz                     Portia                    LoSeasonique* 
(n=1)                                                                                (n=2)            (n=1) 
 
      
________________________________________________________________________ 


























Note:  Levo = Levonorgestrel 
           Nore = Norethindrone 































1 mg Nore 
n=51 










Table 3. Demographic Characteristics by Group 
 
________________________________________________________________________ 
Variable   Control Anti Andro        Highly Andro p 
  (n=45)            (n=49) (n=51)  (n=34) 
 
Age 17.78 (1.69)  18.02 (1.33) 18.06 (1.46) 17.85 (1.73)  .791  
 
Education 11.53 (1.80)  11.65 (1.38) 11.80 (1.52) 11.71 (1.78)  .874  
 
Mother’s  
Education 14.71 (2.50) 14.75 (2.08) 14.61 (2.23) 14.74 (2.22) .990 
 
Father’s  
Education 14.89 (3.02) 14.83 (2.99) 14.14 (2.17) 14.91 (2.29) .442 
 
WRAT-IV (SS) 105.93 (13.07)  101.92 (13.61) 103.14 (12.26) 105.44 (12.03)  .398  
 
 
Race      .485 
 Caucasian 38 (84.4%)  40 (81.7%) 43 (84.3%) 26 (76.5%) 
   
 Af. American   3 (6.7%)    6 (12.2%)   2 (3.9%)   2 (5.9%)   
 
 Multi-Race   4 (8.9%)    3 (6.1%)   6 (11.8%)   6 (17.6%) 
 
 
Ethnicity      .655 
 Non-Hispanic 42 (93.3%)   44 (89.9%) 49 (96.1%) 31 (91.2%)   
 
 Hispanic/Latino   3 (6.7%)    5 (10.1%)   2 (3.9%)   3 (8.8%)   
 
 
Lifetime Depressive Symptoms      .365 
 None 24 (53.3%)  16 (32.7%) 27 (52.9%) 14 (41.2%)  
  
 Mild/Moderate   7 (15.6%)  12 (24.6%) 11 (21.6%)   8 (23.5%)   
 
 Severe 14 (31.1%)  21 (42.9%) 13 (25.5%) 12 (35.3%) 
 
________________________________________________________________________ 
Note: Data are presented as means (standard deviations) or number (percentage)  
 




Table 4. Means and Standard Deviations for Outcome Measures 
 
________________________________________________________________________ 
Variable            Anti                  Control             Andro     Highly Andro        Total 
                        (n=49)                (n=45)              (n=51)         (n=34)             (n=179) 
________________________________________________________________________ 
 
PLOT        47.02 (17.96)     45.83 (19.34)    46.73 (18.15)    48.16 (15.96)    46.86 (18.88) 
 
PMAT 64.09 (16.23) 62.56 (18.42) 66.69 (19.52) 58.70 (19.9)      63.42 (18.52) 
 
CPW 94.69 (5.97)  93.56 (8.60) 93.63 (5.94) 95.37 (5.54)      94.23 (6.64) 
 
SPVRT 84.90 (9.98)  85.04 (14.22) 87.58 (11.70) 89.22 (10.38)    86.52 (11.76) 
 
ER40 
(Total) 84.69 (5.51) 86.33 (7.16) 87.25 (6.69) 87.72 (4.98)      86.41 (6.28) 
 
ER40 
(Anger) 68.11 (17.50) 74.17 (17.35) 73.28 (16.59) 73.90 (15.50)    72.21 (16.89) 
 
MEDF 
(Total) 79.28 (7.45) 77.05 (8.25) 78.61 (7.73) 81.85 (8.21)      79.01 (7.98) 
 
MEDF 
(Anger) 80.68 (11.12) 79.66 (12.73) 81.27 (10.82) 83.73 (12.14)    81.17 (11.64) 
________________________________________________________________________ 




















Table 5. One-Way ANOVAs for Effects of Androgenicity on Outcome Measures 
 
______________________________________________________________ 
Variable F(2, 178)     p η2  
______________________________________________________________      
 
PLOT .11 .954 .002  
 
PMAT 1.33 .267 .022 
 
CPW .71 .551 .012  
 
SPVRT 1.29 .280 .022 
 
ER40-Total 2.06 .107 .034  
 
ER40-Anger 1.35 .259 .023 
 
MEDF-Total 2.46 .064 .040  
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Variables                          F(6, 348)             p             Wilk's Λ             η2  
______________________________________________________________      
 
ER40-Total    
MEDF-Total 2.23 .040 .927             .037  
  
_______________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
